Recent Finacing
Recent Raise
3T Biosciences develops T‑cell therapies using its 3T‑TRACE platform that combines high‑diversity target libraries and active machine learning to identify immunogenic solid‑tumor targets, TCRs/TCR‑mimetics, and screen off‑target reactivity.
